Applications ⇢

Efficacy Screening Services

Advance your candidate program at speed through the provision of phenotypically relevant human data

Leverage our drug discovery expertise

DefiniGEN's Phenotypic Screening Service helps you move quickly and efficiently from screening library to promising candidates by combining our expertise at generating iPSC-derived hepatocyte cellular models of disease with our wide panel of bespoke bioassays.

We work as partners with your team to design and implement in-house screening of:

Small molecules
GalNAc conjugates
RNAi/oligonucleotide therapeutics
AAVs
Plasmids
Lentiviral vectors
Many other therapeutic modalities so you can advance your program at speed

Why choose DefiniGEN?

Choosing DefiniGEN's efficacy screening services offers more than just extra hands and fully equipped labs. We aim to work with your team collaboratively to ensure that you get the most informative and actionable data as efficiently as possible.

DefiniGEN becomes your scientific partner, providing expertise in

Cell-based assays

Assay development

Lead optimization

More than just extra hands and fully equipped labs

Advance any therapeutic modality

RNAi therapeutics

Small molecules

Gene therapeutics

And more

Bespoke modelling available

Use pre-made or custom iPSC-derived hepatocyte models to fit your project specific requirements

Optimized Bioassay development

Quantify cell viability, proliferation, apoptosis and more. Leverage our fully equipped labs and drug discovery expertise

Experts in gene therapy

We have 7+ years of successfully completed projects that we continue to build on

In-house drug screening platform capabilities, advancing your programme at speed

Using our OptiDIFF platform technology alongside CRISPR gene-editing capabilities, we can generate a wide range of disease models to support hit to lead compound profiling initiatives.

And, of course you get access to our proprietary OptiDIFF platform, which is well known for generating iPSC-derived models for even "difficult" target cell types such as hepatocytes, intestinal cells and organoids.

Technology

Flow cytometers

Confocal microscopes

Fluorescence intensity (incl. FRET)

Fluorescence polarization,

Luminescence (flash and glow) - incl. BRET,

Time-resolved fluorescence, TR-FRET,

UV/vis absorbance spectra

qPCR profiling

Phenotypic Assays

Cell viability

LDH (cell death/ cytotoxicity)

Reactive oxygen species assay

PAS/Diastase staining

BODIPY fatty acid accumulation

Copper accumulation

FOCI A1AT assay

Let us know your assay requirements

Project workflow

01 →

Project consultation - Choose/develop a model

Our team of experts will structure a study according to your project specific requirements.

02 →

Select your assay and send us your compounds

Depending on your therapeutic modality, our team optimize treatment windows and dosing accordingly.

We work as a research partner

Offering bi-weekly updates and interim reporting.

In-house drug screening platform capabilities

Move even faster by screening your candidates on our already built and ready-to-use validated models. Explore our models further...

PFIC2
MASLD
A1ATD
Wilson’s Disease
OTC
Custom models

Let’s work together

Contact us to discuss your project with one of our experts